CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Biontech SE - BNTX CFD

142.59
1.06%
1.32
Low: 140.48
High: 143.69
Market Trading Hours* (UTC) Opens on Monday at 09:10

Mon: 09:10 - 00:00

Tue - Thu: 00:00 - 01:00 09:10 - 00:00

Fri: 00:00 - 01:00 09:10 - 22:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 1.32
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.006402 %
Charges from borrowed part ($-0.26)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.006402%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.005927 %
Charges from borrowed part ($-0.24)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.005927%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 141.09
Open* 141.49
1-Year Change* -11.01%
Day's Range* 140.48 - 143.69
52 wk Range 117.08-188.99
Average Volume (10 days) 809.60K
Average Volume (3 months) 19.56M
Market Cap 34.59B
P/E Ratio 3.21
Shares Outstanding 242.52M
Revenue 20.22B
EPS 44.44
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 27, 2023 142.59 1.13 0.80% 141.46 143.82 140.03
Jan 26, 2023 141.09 -1.98 -1.38% 143.07 143.84 140.37
Jan 25, 2023 142.22 -0.87 -0.61% 143.09 144.55 140.99
Jan 24, 2023 143.27 0.08 0.06% 143.19 144.16 140.65
Jan 23, 2023 143.73 0.95 0.67% 142.78 144.84 141.38
Jan 20, 2023 142.49 1.65 1.17% 140.84 143.35 138.99
Jan 19, 2023 140.39 -2.69 -1.88% 143.08 143.94 139.57
Jan 18, 2023 142.94 -0.98 -0.68% 143.92 147.66 142.74
Jan 17, 2023 144.32 -0.11 -0.08% 144.43 145.61 140.88
Jan 13, 2023 144.49 -5.59 -3.72% 150.08 151.01 141.99
Jan 12, 2023 149.04 0.05 0.03% 148.99 150.56 146.19
Jan 11, 2023 148.99 -5.98 -3.86% 154.97 155.85 146.75
Jan 10, 2023 153.29 4.35 2.92% 148.94 154.16 147.14
Jan 9, 2023 148.56 -1.93 -1.28% 150.49 152.89 148.56
Jan 6, 2023 149.59 4.39 3.02% 145.20 155.90 144.53
Jan 5, 2023 145.18 -0.73 -0.50% 145.91 147.59 143.59
Jan 4, 2023 145.99 -3.61 -2.41% 149.60 151.83 145.72
Jan 3, 2023 147.99 -2.66 -1.77% 150.65 154.92 147.99
Dec 30, 2022 151.03 -1.78 -1.16% 152.81 153.91 145.89
Dec 29, 2022 153.24 1.25 0.82% 151.99 156.01 151.99

Biontech SE Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total revenue 61.598 127.575 108.589 482.325 18976.7
Revenue 61.598 127.575 108.589 482.325 18976.7
Cost of Revenue, Total 9.318 13.69 17.361 59.333 2911.5
Gross Profit 52.28 113.885 91.228 422.992 16065.2
Total Operating Expense 122.875 181.429 290.107 564.742 3692.9
Selling/General/Admin. Expenses, Total 29.493 27.07 44.45 103.457 328.9
Research & Development 75.637 124.728 197.893 614.837 916.3
Depreciation / Amortization 10.489 20.617 32.388 35.296 40.2
Unusual Expense (Income) 0.281 0 -137.2
Other Operating Expenses, Total -2.343 -4.676 -1.985 -248.181 -1.1
Operating Income -61.277 -53.854 -181.518 -82.417 15283.8
Interest Income (Expense), Net Non-Operating -24.575 6.24 2.404 -60.337 -215.5
Other, Net -0.053 -0.048 -0.326 -3.048 -21.9
Net Income Before Taxes -85.905 -47.662 -179.44 -145.802 15046.4
Net Income After Taxes -85.95 -48.262 -179.172 15.198 10292.5
Minority Interest 0.297 0.243 0.116 0
Net Income Before Extra. Items -85.653 -48.019 -179.056 15.198 10292.5
Net Income -85.653 -48.019 -179.056 15.198 10292.5
Income Available to Common Excl. Extra. Items -85.653 -48.019 -179.056 15.198 10292.5
Income Available to Common Incl. Extra. Items -85.653 -48.019 -179.056 15.198 10292.5
Diluted Net Income -85.653 -48.019 -179.056 15.198 10292.5
Diluted Weighted Average Shares 226.262 226.262 210.654 253.3 259.7
Diluted EPS Excluding Extraordinary Items -0.37856 -0.21223 -0.85 0.06 39.6323
Diluted Normalized EPS -0.37775 -0.21223 -0.85 0.06 39.2709
Interest Expense (Income) - Net Operating -365.7
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 2048.4 5308.5 6087.3 5532.5 6374.6
Revenue 2048.4 5308.5 6087.3 5532.5 6374.6
Cost of Revenue, Total 233.1 883.8 1211.4 583.2 1294.1
Gross Profit 1815.3 4424.7 4875.9 4949.3 5080.5
Total Operating Expense 386.2 1110.1 1363.8 832.8 1621.9
Selling/General/Admin. Expenses, Total 47.6 59.8 76.9 145.9 105.1
Research & Development 208.7 194 251.9 261.7 275
Depreciation / Amortization 7.5 8.4 10.3 12.7 10.8
Interest Expense (Income) - Net Operating -40.7 -34.4 -165.4 -125.2 -126.8
Unusual Expense (Income) -67.9 -0.1 -20.9 -48.3 0
Other Operating Expenses, Total -2.1 -1.4 -0.4 2.8 63.7
Operating Income 1662.2 4198.4 4723.5 4699.7 4752.7
Interest Income (Expense), Net Non-Operating -17.4 -170.9 -55.7 28.5 268
Other, Net -2.5 -4.7 -0.4 -14.3 -2.6
Net Income Before Taxes 1642.3 4022.8 4667.4 4713.9 5018.1
Net Income After Taxes 1128.1 2787.2 3211 3166.2 3698.8
Net Income Before Extra. Items 1128.1 2787.2 3211 3166.2 3698.8
Net Income 1128.1 2787.2 3211 3166.2 3698.8
Income Available to Common Excl. Extra. Items 1128.1 2787.2 3211 3166.2 3698.8
Income Available to Common Incl. Extra. Items 1128.1 2787.2 3211 3166.2 3698.8
Diluted Net Income 1128.1 2787.2 3211 3166.2 3698.8
Diluted Weighted Average Shares 243.125 244.063 260 260.253 243.125
Diluted EPS Excluding Extraordinary Items 4.64 11.42 12.35 12.1658 15.2136
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 4.44816 11.4197 12.2947 12.0412 15.2136
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Total Current Assets 189.637 448.961 560.151 1666.9 15072.3
Cash and Short Term Investments 172.352 411.831 520.829 1347.44 2074.3
Cash 172.106 411.495 519.149 1210.21 1692.7
Short Term Investments 0.246 0.336 1.68 137.234 381.6
Total Receivables, Net 9.094 28.44 20.205 170.521 12382.1
Accounts Receivable - Trade, Net 4.575 18.938 11.913 165.468 12381.7
Total Inventory 3.876 5.789 11.722 64.12 502.5
Prepaid Expenses 0.815 0.155 0.351 29.845
Other Current Assets, Total 3.5 2.746 7.044 54.967 113.4
Total Assets 374.713 652.986 797.647 2318.62 15830.8
Property/Plant/Equipment, Total - Net 101.522 115.965 148.062 325.956 520.4
Property/Plant/Equipment, Total - Gross 129.225 152.617 197.345 384.288 594.6
Accumulated Depreciation, Total -27.703 -36.652 -49.285 -58.332 -74.2
Goodwill, Net 0.534 0.534 2.978 53.697 57.8
Intangibles, Net 83.003 87.508 86.456 109.793 144.6
Long Term Investments 0.019 0.018 0 21.3
Other Long Term Assets, Total -0.002 0 162.278 14.4
Total Current Liabilities 158.544 126.121 138.142 606.014 3481.6
Accounts Payable 52.538 41.721 20.498 102.288 160
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.832 8.266 3.485 6.127 129.9
Other Current Liabilities, Total 104.174 76.134 114.159 497.599 3191.7
Total Liabilities 424.009 386.833 304.155 946.774 3937.1
Total Long Term Debt 0 5.6 68.904 231.047 171.6
Long Term Debt 0 5.6 14.777 153.016 17.9
Minority Interest 1.09 0.847 0
Other Liabilities, Total 264.375 254.265 97.109 109.432 217.2
Total Equity -49.296 266.153 493.492 1371.85 11893.7
Common Stock 166.764 193.296 232.304 246.31 246.3
Retained Earnings (Accumulated Deficit) -216.06 72.857 266.713 1130.32 11651.2
Total Liabilities & Shareholders’ Equity 374.713 652.986 797.647 2318.62 15830.8
Total Common Shares Outstanding 226.262 226.262 226.78 241.521 242.521
Capital Lease Obligations 54.127 78.031 153.7
Treasury Stock - Common -5.525 -4.789 -3.8
Deferred Income Tax 0.281 66.7
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 3536 8439.5 13551.4 15072.3 19466.1
Cash and Short Term Investments 892 914.9 2394.5 2074.3 6165
Cash 891.5 914.1 2392.7 1692.7 6164.1
Short Term Investments 0.5 0.8 1.8 381.6 0.9
Total Receivables, Net 2396 7052.6 10604.8 12382.1 12696.2
Accounts Receivable - Trade, Net 2395.1 7051.7 10603.9 12381.7 12695.8
Total Inventory 146.9 305.4 393.4 502.5 459.3
Other Current Assets, Total 101.1 166.6 158.7 113.4 145.6
Total Assets 4204.7 9148.8 14232.6 15830.8 20299.6
Property/Plant/Equipment, Total - Net 360.8 381.1 442.1 520.4 556.9
Intangibles, Net 165.2 164.1 162.9 202.4 216
Other Long Term Assets, Total 142.7 164.1 76.2 14.4 12.2
Total Current Liabilities 1311.1 3163.3 4902.6 3481.6 3854.5
Accounts Payable 106.2 262.7 258.9 160 123.7
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 18 13.9 19 129.9 30.6
Other Current Liabilities, Total 1186.9 2886.7 4624.7 3191.7 3700.2
Total Liabilities 1685.1 3666 5521.1 3937.1 4388.9
Total Long Term Debt 236.6 242.9 267.7 171.6 155.4
Long Term Debt 236.6 242.9 267.7 171.6 155.4
Deferred Income Tax 0 0 0 66.7 50.9
Other Liabilities, Total 137.4 259.8 350.8 217.2 328.1
Total Equity 2519.6 5482.8 8711.5 11893.7 15910.7
Common Stock 246.3 246.3 246.3 246.3 246.8
Retained Earnings (Accumulated Deficit) 2278.1 5240.3 8469 11651.2 15667.7
Treasury Stock - Common -4.8 -3.8 -3.8 -3.8 -3.8
Total Liabilities & Shareholders’ Equity 4204.7 9148.8 14232.6 15830.8 20299.6
Total Common Shares Outstanding 241.521 241.521 241.521 242.521 242.521
Long Term Investments 21.3 48.4
  • Annual
  • Quarterly
2017 2018 2019 2020 2021
Net income/Starting Line -85.905 -47.662 -179.44 -145.802 15046.4
Cash From Operating Activities -52.562 -58.877 -198.537 -13.474 889.7
Cash From Operating Activities 10.529 21.984 33.896 38.744 75.2
Non-Cash Items 29.416 7.943 31.109 188.487 -32.6
Cash Taxes Paid 0.045 0.304 -0.122 -0.378 3457.9
Cash Interest Paid 0.729 1.769 2.044 3.628 12.2
Changes in Working Capital -6.602 -41.142 -84.102 -94.903 -14199.3
Cash From Investing Activities -52.549 -66.452 -77.115 -144.848 -566.1
Capital Expenditures -57.742 -67.157 -71.08 -85.446 -154
Other Investing Cash Flow Items, Total 5.193 0.705 -6.035 -59.402 -412.1
Cash From Financing Activities -1.643 365.177 383.29 894.725 94.2
Issuance (Retirement) of Stock, Net 0 361.725 375.351 753.007 160.9
Issuance (Retirement) of Debt, Net -1.643 3.452 7.939 141.718 -66.7
Foreign Exchange Effects -24.82 -0.459 0.016 -45.343 64.7
Net Change in Cash -131.574 239.389 107.654 691.06 482.5
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 1642.3 5665.1 10332.5 15046.4 5018.1
Cash From Operating Activities -311.3 -411.6 1089.2 889.7 4050.2
Cash From Operating Activities 13 29.4 49.2 75.2 27.6
Non-Cash Items -37.2 69.3 -15.6 -32.6 -197
Cash Taxes Paid 0.1 0.3 1 3457.9 1290
Cash Interest Paid 1.8 3.9 6.1 12.2 6.4
Changes in Working Capital -1929.4 -6175.4 -9276.9 -14199.3 -798.5
Cash From Investing Activities -28.3 -58.1 -99.2 -566.1 287.4
Capital Expenditures -29.2 -59.3 -100.6 -154 -60.8
Other Investing Cash Flow Items, Total 0.9 1.2 1.4 -412.1 348.2
Cash From Financing Activities -4.5 148.4 143.1 94.2 80.3
Issuance (Retirement) of Debt, Net -4.5 -12.5 -17.8 -66.7 -30.2
Foreign Exchange Effects 25.4 25.2 49.4 64.7 53.5
Net Change in Cash -318.7 -296.1 1182.5 482.5 4471.4
Issuance (Retirement) of Stock, Net 160.9 160.9 160.9 110.5
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
AT Impf GmbH Corporation 43.7253 106114901 -8295437 2021-12-31
Medine GmbH Corporation 17.1027 41505853 -157577 2021-12-31
Baillie Gifford & Co. Investment Advisor 3.1803 7718123 473051 2022-12-31 LOW
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund 1.804 4378022 3840388 2022-09-30 LOW
PRIMECAP Management Company Investment Advisor 1.7283 4194388 -6910 2022-09-30 LOW
Flossbach von Storch AG Investment Advisor 1.3864 3364564 299414 2022-09-30 LOW
Artisan Partners Limited Partnership Investment Advisor 0.9184 2228913 1487687 2022-09-30 LOW
Huber (Christoph M.D.) Individual Investor 0.825 2002040 -200000 2021-12-31
Jeggle (Helmut) Individual Investor 0.7936 1925967 -300000 2021-12-31 LOW
Capital Research Global Investors Investment Advisor 0.7598 1843891 329510 2022-12-31 LOW
Capital World Investors Investment Advisor 0.6695 1624662 880179 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6069 1472867 -98301 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 0.5177 1256309 -591626 2022-09-30 LOW
Fosun International Ltd Investment Advisor 0.3138 761538 -242102 2022-09-30 LOW
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH Investment Advisor 0.303 735400 -1200 2022-11-30 LOW
Marett (Sean) Individual Investor 0.2909 705936 -280000 2021-12-31
DWS Investment GmbH Investment Advisor/Hedge Fund 0.2481 602103 -4086 2022-09-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 0.2411 585125 -40964 2022-09-30 LOW
Baillie Gifford Overseas Ltd. Investment Advisor 0.227 550905 15695 2022-11-30 HIGH
Poetting (Sierk) Individual Investor 0.2168 526062 -128325 2021-12-31

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+485000+

Traders

65000+

Active clients monthly

$48000000+

Monthly investing volume

$28000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Biontech SE Company profile

Discover the latest BioNTech stock price today with our interactive streaming chart.

Founded in 2008, BioNTech is an innovative biotechnology company from Germany, specialising in the research, development and producing of active individualised immunotherapies. The company adheres to a patient-specific approach to treatment of serious diseases, such as cancer.

BioNTech shares a vision that every patient’s tumour is unique. It means that each patient’s treatment should be individualised. To implement the scientists’ ideas into practice, BioNTech has developed pioneering therapeutics for cancer and other rare and infectious diseases.

Headquartered in Mainz, Germany, the company is aimed at becoming the world’s leading biotechnology company for individialised cancer treatment. By 2020, BioNTech had more than 440 patients treated across 17 tumour types. The company has more than 1,300 employees and seven pharmaceutical partners.

In August 2018, the company partnered with the US pharmaceutical giant Pfizer Inc to develop mRNA-based vaccines for preventing influenza. In September 2019, BioNTech started working on the development of tuberculosis and HIV programmes and preclinical vaccine and immunotherapy candidates for the prevention of tuberculosis and HIV infections under an agreement with the Bill & Melinda Gates Foundation.

BioNTech stock floated on the NASDAQ stock exchange through a $150m initial public offering (IPO) in October 2019. Since then the BNTX stock quote has been traded on the US market.

In November 2020, BioNTech and Pfizer triggered the strongest wave of optimism on the stock market after they announced that their Covid-19 vaccine showed 90 per cent effectiveness during the phase-three clinical trials. The BioNTech share price soared 14 per cent the day after the announcement.

In 2019, BioNTech reported total revenues of about €109m. According to the estimates from Morgan Stanley, BioNTech and Pfizer can make around $13bn from vaccine sales, getting $6.5bn each if these estimates are correct.

Looking closely at the BioNTech stock price chart in 2020, we can see that BNTX stock has been trading in a range of $18.60-$115. Since the large sell-off in March 2020, the BioNTech SE (BNTX) stock quote grew from $28.55 on March 12, 2020, to $112.76 on November 10, 2020, which is a growth of 294 per cent.

Follow the BioNTech share price live on our interactive share price chart and build your own forecast for the famous German biotechnology company. Follow the latest BioNTech share news and spot the best levels to open profitable CFD trades at Capital.com.

Industry: Bio Therapeutic Drugs

An der Goldgrube 12
MAINZ
RHEINLAND-PFALZ 55131
DE

Income Statement

  • Annual
  • Quarterly

People also watch

XRP/USD

0.41 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00352

Natural Gas

2.86 Price
+0.740% 1D Chg, %
Long position overnight fee -0.0485%
Short position overnight fee 0.0282%
Overnight fee time 22:00 (UTC)
Spread 0.005

ETH/USD

1,594.01 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 5.50

US100

12,164.80 Price
+1.340% 1D Chg, %
Long position overnight fee -0.0179%
Short position overnight fee 0.0070%
Overnight fee time 22:00 (UTC)
Spread 3.0
video

Still looking for a broker you can trust?

Join the 480.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading